Tigecycline In-Vitro Surveillance Study In Taiwan

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00488397

Enrollment

7902

Registered

2007-06-20

Start date

2006-08-31

Completion date

2011-02-28

Last updated

2011-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Infections

Keywords

Tygacil, microdilution method, Tigecycline, In-Vitro

Brief summary

In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.

Interventions

OTHERIn-vitro testing

This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Clinically relevant causative isolate (no duplicates) - The isolate must meet the laboratory criteria of significant pathogen and be considered the probable causative agent of a hospital or community acquired infection. * Sources - All body sites are acceptable clinical sources for isolates to be included in this study (Intra-abdominal infection, tracheal secretion/bronchoalveolar lavage, blood culture, wound smear). However, no more than 10 % of all isolates can come from urine cultures. * Within study group - Only isolates defined by the protocol are to be included.

Exclusion criteria

* Limited isolates from sources - No more than 10 % of all isolates from this study will be derived from urine cultures. * No banked or stored isolates. * No duplicate isolates - Only one isolate per patient is permitted. * Outside study group - Any isolate other than those defined by protocol.

Design outcomes

Primary

Measure	Time frame
Prior to 2009: Susceptibility data of minimum inhibitory concentration (MIC), MIC50, MIC90by pathogen, tested by E-test.	in vitro study therefore not applicable
Post-2009: Susceptibility data of MIC, MIC50, MIC90 by pathogen, tested by micro-dilution method	in vitro study therefore not applicable

Secondary

Measure	Time frame
Prior to 2009: 1. Susceptibility data of minimum inhibitory concentration (MIC), MIC50, MIC90 by pathogen, tested by micro-dilution method 2. Susceptibility data of inhibition zone diameter(mm) by pathogen, tested by paper disc.	in vitro study therefore not applicable
Post-2009: Susceptibility data of inhibition zone diameter (mm) by pathogen, tested by paper disc.	in vitro study therefore not applicable

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026